New study tackles cultural gaps in prostate cancer care for latiné men
NCT ID NCT06435871
First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times
Summary
This study looks at how Spanish-speaking Latiné men cope after prostate cancer treatment, especially with issues like erectile dysfunction and urinary problems. Researchers will survey and interview 55 survivors to understand their needs and cultural barriers. The goal is to create better, language-friendly resources like Spanish videos to help them make informed decisions about their health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- questionnaires and focus groups (behavioural intervention)
- What this could lead to
- If successful, this could lead to culturally tailored educational videos and decision aids for Spanish-speaking Latiné prostate cancer survivors, improving their quality of life and informed decision-making.
- What could go wrong
- This is a small, early-stage study (55 participants) focused on gathering opinions, not testing a treatment. The findings may not apply to all Latiné groups or lead to measurable health improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
55 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Jul 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults \>18 years * Diagnosis of Localized Prostate Cancer * Underwent radical prostatectomy by their urological surgeon * Subjects must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patient whose primary language is not English or Spanish * Patients who had brachytherapy and/or radiation treatment as their initial treatment * Patients with disease progression at time study recruitment who are requiring other treatments (ADT, chemotherapy, immunotherapy) * Patients who underwent current non-standard prior treatment options for localized prostate cancer including cryotherapy and high intensity focused ultrasound (HIFU)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Light-Based imaging aims to spot prostate cancer left behind after surgery
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer